Floatz logo
Floatz Rating
B56/100
Confidence
Indicative
v0.2
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07532902CT.gov
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
—Recruiting———
NCT06047379CT.gov
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
—Recruiting———
NCT05176483CT.gov
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
—Recruiting———
NCT04388852CT.gov
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
—Active Not Recruiting———
NCT03752398CT.gov
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
—Completed———
NCT03639714CT.gov
A Study of a Personalized Neoantigen Cancer Vaccine
—Completed———
NCT02983045CT.gov
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Urothelial Carcinoma

AssetSponsorPhaseRating
Ipilimumab (this asset)Memorial Sloan Kettering Cancer CenterP1/2B · 56
CyclophosphamideBeijing BiotechP3BB
Cis-Diamminedichloroplatinum IiNagoya UniversityP3BB
DurvalumabAlliance for Clinical Trials in OncologyP3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncP2/3BB
PembrolizumabSutro Biopharma, Inc.P3BB
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, DimerEli Lilly and CompanyP3BB
DocetaxelNuCana plcP3BB
RetifanlimabIncyte CorporationP2BB

+42 more in the Urothelial Carcinoma cohort

Other indications for Ipilimumab

IndicationSponsorPhaseRating
Metastatic Neoplasm—P3BB · 71
Melanoma—P4BB · 69
Cutaneous Melanoma—P3BB · 69

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Ipilimumab in Urothelial Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/ipilimumab-urothelial-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →